Anatara Lifesciences Ltd (ASX:ANR) Animal Health Update
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on challenge trials of select Anatara animal health assets.
Companies in the News
Drugs & OTC
Anatara Lifesciences Ltd (ASX:ANR) $1.4m Raised Through the Completed SPP
Anatara Lifesciences (ASX:ANR) is pleased to advise that the Share Purchase Plan (SPP) announced to the market on 21 October 2020 closed on 11 November 2020 oversubscribed.
AusCann Group Holdings Ltd (ASX:AC8) and CannPal Enter Into Scheme of Arrangement
AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.
Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at AusBiotech +Invest 2020.
Anatara Lifesciences Ltd (ASX:ANR) Quarterly Financial Report
Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2020. The Company's cash plus term deposits at the end of the quarter stood at $1.59m (30th June 2020: $2.7m). On 30th September 2020, the Company had cash at bank of $1.09m and $0.5m in term deposits.
Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders
Anatara Lifesciences Ltd (ASX:ANR) is developing an OTC medicine to address factors associated with gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): microbiome dysbiosis, inflammation and mucosal damage.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore to Present at AusBiotech 2020
Anatara's CEO, Steve Lydeamore will be presenting to investors at AusBiotech + Invest 2020 on 29th October 2020. Register to attend free for qualified investors.
◂Previous Page
Drugs & OTC Next Page▸
Banking & Finance
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
- NSX Limited (ASX:NSX) Appointment of Managing Director and CEO - Max Cunningham
Social Media
